Core Insights - BullFrog AI Holdings, Inc. has entered a collaboration with Eleison Pharmaceuticals to enhance clinical trial efficiency and patient insights using its BullFrog Data Networks™ AI solution [1][2] - The partnership aims to apply AI technology to analyze clinical data from Eleison's ongoing Phase 3 trial of glufosfamide, a treatment for pancreatic cancer, to improve trial design and decision-making [2][3] Company Overview - BullFrog AI is a technology-enabled drug development company that utilizes artificial intelligence and machine learning to facilitate the development of pharmaceuticals and biologics [1][4] - Eleison Pharmaceuticals focuses on developing novel chemotherapeutic treatments for rare cancers and has multiple programs in late-stage clinical development, including glufosfamide for pancreatic cancer [5] Clinical Trial Details - Glufosfamide is currently being evaluated in a pivotal Phase 3 international randomized clinical trial for second-line treatment of pancreatic cancer, which is a leading cause of cancer-related deaths in the U.S. [3] - The ongoing Phase 3 trial is expected to be completed by 2027, with glufosfamide designed to have greater specificity and reduced systemic toxicities compared to traditional treatments [3] Strategic Implications - The collaboration is expected to generate deeper insights into patient responses and safety trends, benefiting not only the glufosfamide program but also Eleison's broader oncology pipeline [4] - BullFrog AI's bfLEAP platform will evaluate safety signals and extract predictive biomarkers to support future trial designs, potentially accelerating the path to market for life-saving therapies [2][4]